Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc.…

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Na

Event · Listing notice
Exchange
The Nasdaq Stock Market LLC
Kind
deficiency
Rule
Nasdaq Listing Rule 5550(a)(2)
Also in this documentStock split

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 9:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$SXTP
Bearish
high confidence
Mentioned
$SXTP
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SXTPBearishHigh
01

Why it matters

The company faces scheduled delisting and trading suspension unless it appeals by Nov. 27, 2026. It also plans a reverse stock split expected to become effective Dec. 2, 2026 to attempt to regain compliance.

02

Market read

This is a direct exchange-action event with defined deadlines (appeal by Nov. 27, suspension Dec. 1) and an announced corporate action (reverse split effective Dec. 2) that can materially change trading risk.

03

What to watch

Traders should monitor whether the reverse split is actually executed on Dec. 2 and whether the Panel grants continued listing, since either outcome can sharply change expected delisting timing.

Relevance 9/10Novelty 8/10Timing: Appeal deadline is Nov. 27, 2026, with potential trading suspension at the Dec. 1, 2026 open.

Background

Nasdaq notified the company it failed the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and because of prior reverse splits it is not eligible for a compliance period.

Company-level read

Ticker impact

$SXTPBearishHigh confidence
Context

60 Degrees Pharmaceuticals disclosed Nasdaq staff determined it failed the $1 bid-price rule and will be delisted unless it appeals by Nov. 27.

Expected impact

Likely downward pressure as traders price in delisting risk, with volatility around the appeal deadline and any Panel decision.

Evidence & confidence

The filing states Nasdaq will schedule delisting and suspend trading Dec. 1 unless an appeal is requested by Nov. 27, and it also confirms a planned reverse split to try to regain compliance.

Market effects

No direct sector read-through beyond heightened scrutiny of micro-cap biotech listing compliance risk.

Limited spillover expected, but it can add to Nasdaq small-cap stress sentiment.

Primarily US listing mechanics, with minimal global relevance.

Counterpoint

The reverse split and requested Hearings Panel stay could reduce immediate delisting probability, so the stock may trade as an event-driven rebound rather than a straight fade.

Key entities

  • 60 Degrees Pharmaceuticals, Inc.

    Nasdaq-listed company receiving the delisting notice and planning a reverse stock split.

  • Nasdaq Stock Market LLC

    Exchange staff issued the delisting determination under the bid price rule.

  • Nasdaq Listing Qualifications Department

    Staff that determined the company is not in compliance and will be delisted.

  • Nasdaq Hearings Panel

    Panel that can stay suspension pending decision if an appeal is requested.

Related articles

$SXTPMedAI 8/10

60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down

60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.

$SXTPMedAI 8/10

60 Degrees Pharmaceuticals (SXTP) Reports PCR-Negative Outcomes in 5 Babesiosis Patients

60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.

$SXTPMedAI 8/10

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

$SXTPMedAI 8/10

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on